A corrupt Florida oncologist who victimized vulnerable cancer patients under her care by exposing them to illegal, foreign-sourced medications is facing serious prison time. D. Anda Norbergs was convicted by a federal jury yesterday on multiple misbranding, smuggling, health care fraud, and mail fraud charges, according to a U.S. Department of Justice (DOJ) press release.
Instead of receiving FDA-approved oncology drugs from legitimate suppliers, cancer patients at Norbergs’ East Lake Oncology (ELO) clinic in Palm Harbor, Florida were unknowingly administered drugs that were manufactured and packaged for distribution in countries like Turkey, India, and Germany and purchased by ELO from unlicensed overseas suppliers, like Quality Specialty Products (QSP).
Even after learning that QSP was implicated in the 2012 counterfeit Avastin episode, Norbergs continued to administer QSP’s drugs to her patients. And when QSP was shut down, Norbergs simply found another foreign supplier to take their place.
This type of despicable conduct from trusted medical professionals is becoming far too commonplace. Vulnerable patients will remain at risk unless diversion and counterfeiting schemes that increasingly threaten our nation’s pharmaceutical distribution supply chain are rooted out by regulatory and law enforcement authorities with greater frequency. Maintaining the status quo only guarantees that greedy fraudsters like Norbergs will continue to thrive and growing numbers of patients will be exposed to drugs of unknown safety and origin.